Literature DB >> 11363534

FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. Food and Drug Administration.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 11363534

Source DB:  PubMed          Journal:  J Int Assoc Physicians AIDS Care        ISSN: 1081-454X


× No keyword cloud information.
  6 in total

1.  Clinical Cancer Nanomedicine.

Authors:  Joy Wolfram; Mauro Ferrari
Journal:  Nano Today       Date:  2019-03-06       Impact factor: 20.722

Review 2.  Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.

Authors:  Fatemeh Farjadian; Amir Ghasemi; Omid Gohari; Amir Roointan; Mahdi Karimi; Michael R Hamblin
Journal:  Nanomedicine (Lond)       Date:  2018-11-19       Impact factor: 5.307

Review 3.  Factors affecting the clearance and biodistribution of polymeric nanoparticles.

Authors:  Frank Alexis; Eric Pridgen; Linda K Molnar; Omid C Farokhzad
Journal:  Mol Pharm       Date:  2008-08-04       Impact factor: 4.939

Review 4.  Rational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice.

Authors:  Sabrina Valetti; Simona Mura; Barbara Stella; Patrick Couvreur
Journal:  J Nanobiotechnology       Date:  2013-12-10       Impact factor: 10.435

Review 5.  Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination.

Authors:  Ai-Ming Yu; Mei-Juan Tu
Journal:  Pharmacol Ther       Date:  2021-08-14       Impact factor: 13.400

6.  Cationic liposomes induce cytotoxicity in HepG2 via regulation of lipid metabolism based on whole-transcriptome sequencing analysis.

Authors:  Ying Li; Xiu-Liang Cui; Qing-Shan Chen; Jing Yu; Hai Zhang; Jie Gao; Du-Xin Sun; Guo-Qing Zhang
Journal:  BMC Pharmacol Toxicol       Date:  2018-07-11       Impact factor: 2.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.